Background: The majority of bladder cancer patients experience recurrence. Cisplatin is the standard chemotherapy for muscle-invasive bladder cancer though adverse effects are often severe. Case Report:  Intravenous (IV) dicycloplatin (DCP) sustained remission in an American bladder cancer patient for five years. A recurrent mass was observed in July 2021. The patient received DCP capsules for seven weeks with no significant side-effects. Complete blood count with differential and a basic metabolic panel showed no adverse effects of DCP capsules on the bone marrow, liver or renal parameters. Cystoscopy after oral DCP found no evident bladder tumors; cytology was negative for high-grade urothelial carcinoma. Conclusion: In this patient, DCP-capsules appeared to be as effective as DCP-IV for achieving bladder cancer remission. Both forms of DCP chemotherapy are convenient, active against several cancer types, with decreased adverse effects compared to cisplatin. Both have been available for treating cancer patients in China. A USA clinical trial of DCP in bladder and other cancers appears warranted.  

Jing Jie Yu, MD is a Professor Emeritus. After 13 years working at US National Cancer Institute of the National Institutes of Health, she relocated to the school of medicine, West Virginia University, Morgantown, WV. She has been involved in multiple medical and molecular research projects with a focus on platinum compounds. She has contributed to research in topics: Promoter & gene expression and has an index of 2, co-authored 2 publications receiving 50 citations. She is interested in the relationship between platinum-drug resistance and DNA repair mechanisms. Her primary research focus is inhibition of DNA repair pathways by blocking critical genes to overcome platinum resistance, and identification of new drugs for more effective cancer chemotherapy.